TY - JOUR
T1 - Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption
AU - Rothenberger, Meghan K.
AU - Keele, Brandon F.
AU - Wietgrefe, Stephen W.
AU - Fletcher, Courtney V.
AU - Beilman, Gregory J.
AU - Chipman, Jeffrey G.
AU - Khoruts, Alexander
AU - Estes, Jacob D.
AU - Anderson, Jodi
AU - Callisto, Samuel P.
AU - Schmidt, Thomas E.
AU - Thorkelson, Ann
AU - Reilly, Cavan
AU - Perkey, Katherine
AU - Reimann, Thomas G.
AU - Utay, Netanya S.
AU - Makamdop, Krystelle Nganou
AU - Stevenson, Mario
AU - Douek, Daniel C.
AU - Haase, Ashley T.
AU - Schacker, Timothy W.
PY - 2015/3/10
Y1 - 2015/3/10
N2 - Antiretroviral therapy (ART) suppresses HIV replication in most individuals but cannot eradicate latently infected cells established before ART was initiated. Thus, infection rebounds when treatment is interrupted by reactivation of virus production from this reservoir. Currently, one or a few latently infected resting memory CD4 T cells are thought be the principal source of recrudescent infection, but this estimate is based on peripheral blood rather than lymphoid tissues (LTs), the principal sites of virus production and persistence before initiating ART. We, therefore, examined lymph node (LN) and gut-associated lymphoid tissue (GALT) biopsies from fully suppressed subjects, interrupted therapy, monitored plasma viral load (pVL), and repeated biopsies on 12 individuals as soon as pVL became detectable. Isolated HIV RNApositive (vRNA+) cells were detected by in situ hybridization in LTs obtained before interruption in several patients. After interruption, multiple foci of vRNA+ cells were detected in 6 of 12 individuals as soon as pVL was measureable and in some subjects, in more than one anatomic site. Minimal estimates of the number of rebounding/founder (R/F) variants were determined by singlegene amplification and sequencing of viral RNA or DNA from peripheral blood mononuclear cells and plasma obtained at or just before viral recrudescence. Sequence analysis revealed a large number of R/F viruses representing recrudescent viremia from multiple sources. Together, these findings are consistent with the origins of recrudescent infection by reactivation from many latently infected cells at multiple sites. The inferred large pool of cells and sites to rekindle recrudescent infection highlights the challenges in eradicating HIV.
AB - Antiretroviral therapy (ART) suppresses HIV replication in most individuals but cannot eradicate latently infected cells established before ART was initiated. Thus, infection rebounds when treatment is interrupted by reactivation of virus production from this reservoir. Currently, one or a few latently infected resting memory CD4 T cells are thought be the principal source of recrudescent infection, but this estimate is based on peripheral blood rather than lymphoid tissues (LTs), the principal sites of virus production and persistence before initiating ART. We, therefore, examined lymph node (LN) and gut-associated lymphoid tissue (GALT) biopsies from fully suppressed subjects, interrupted therapy, monitored plasma viral load (pVL), and repeated biopsies on 12 individuals as soon as pVL became detectable. Isolated HIV RNApositive (vRNA+) cells were detected by in situ hybridization in LTs obtained before interruption in several patients. After interruption, multiple foci of vRNA+ cells were detected in 6 of 12 individuals as soon as pVL was measureable and in some subjects, in more than one anatomic site. Minimal estimates of the number of rebounding/founder (R/F) variants were determined by singlegene amplification and sequencing of viral RNA or DNA from peripheral blood mononuclear cells and plasma obtained at or just before viral recrudescence. Sequence analysis revealed a large number of R/F viruses representing recrudescent viremia from multiple sources. Together, these findings are consistent with the origins of recrudescent infection by reactivation from many latently infected cells at multiple sites. The inferred large pool of cells and sites to rekindle recrudescent infection highlights the challenges in eradicating HIV.
KW - Founder population
KW - HIV/AIDS
KW - Treatment interruption
KW - Viral recrudescence
UR - http://www.scopus.com/inward/record.url?scp=84924365877&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924365877&partnerID=8YFLogxK
U2 - 10.1073/pnas.1414926112
DO - 10.1073/pnas.1414926112
M3 - Article
C2 - 25713386
AN - SCOPUS:84924365877
SN - 0027-8424
VL - 112
SP - E1126-E1134
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 10
ER -